ReviewClinical microbiology reviews2014
Tissue penetration of antifungal agents.
Review in Clinical microbiology reviews, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 215 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
215 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Population pharmacokinetics of liposomal amphotericin B in adults with HIV-associated cryptococcal meningoencephalitis.The Journal of antimicrobial chemotherapy · 2022Pooled it
- Pharmacokinetic/pharmacodynamics variability of echinocandins in critically ill patients: A systematic review and meta-analysis.Journal of clinical pharmacy and therapeutics · 2020Pooled it
- Pooled it
- Prosthetic Joint Infections Caused by Candida Species: A Systematic Review and a Case Series.Mycopathologia · 2019Pooled it
- Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Inhaled Voriconazole in Healthy Volunteers and Subjects With Stable Asthma.Pharmacology research & perspectives · 2025Trial
- Microdialysis of Voriconazole and its N-Oxide Metabolite: Amalgamating Knowledge of Distribution and Metabolism Processes in Humans.Pharmaceutical research · 2022Trial
- Itraconazole for COVID-19: preclinical studies and a proof-of-concept randomized clinical trial.EBioMedicine · 2021Trial
- Micafungin versus posaconazole prophylaxis in acute leukemia or myelodysplastic syndrome: A randomized study.The Journal of infection · 2018Trial
- Comparative Population Plasma and Tissue Pharmacokinetics of Micafungin in Critically Ill Patients with Severe Burn Injuries and Patients with Complicated Intra-Abdominal Infection.Antimicrobial agents and chemotherapy · 2016Trial
- Article
- Therapeutic Failure in Invasive Fungal Infections: Beyond Antifungal Resistance-A Narrative Review.Journal of fungi (Basel, Switzerland) · 2026Review
- Can Fluconazole Be Used to Treat Non-Resistant Candida (Candidozyma) auris Infections? Preclinical Pharmacokinetic/Pharmacodynamic Data From a Galleria mellonella Infection Model.The Journal of infectious diseases · 2026Article
- Sub-acute Septic Arthritis of the Knee by Candida vishwanathii: Two Rare Case Reports and Review of Literature.Journal of orthopaedic case reports · 2026Article
- Article
- Antemortem diagnosis combining computed tomography and air sac fluid aspiration for aspergillosis: a case report in a gentoo penguin (Pygoscelis papua).The Journal of veterinary medical science · 2026Article
- In Vitro Evaluation of Olorofim and Amphotericin B Combination Therapy AgainstJournal of fungi (Basel, Switzerland) · 2026Article
- Itraconazole as a repurposed anti-cancer agent: focusing on synthesis, mechanisms of action and therapeutic insights.RSC advances · 2026Review
- New and Investigational Treatment Options for Dermatomycosis in the Era of Antifungal Resistance.Journal of fungi (Basel, Switzerland) · 2026Review
- Current and emerging therapies for fungal biofilms and systemic infections.Critical reviews in microbiology · 2026Review
- Ophthalmic Evaluation and Ocular Candidiasis in Patients with Candidemia: A Retrospective Cohort Study from Thailand.Journal of fungi (Basel, Switzerland) · 2026Article
155 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Understanding the tissue penetration of systemically administered antifungal agents is critical for a proper appreciation of their antifungal efficacy in animals and humans. Both the time course of an antifungal drug and its absolute concentrations within tissues may differ significantly from those observed in the bloodstream. In addition, tissue concentrations must also be interpreted within the context of the pathogenesis of the various invasive fungal infections, which differ significantly. There are major technical obstacles to the estimation of concentrations of antifungal agents in various tissue subcompartments, yet these agents, even those within the same class, may exhibit markedly different tissue distributions. This review explores these issues and provides a summary of tissue concentrations of 11 currently licensed systemic antifungal agents. It also explores the therapeutic implications of their distribution at various sites of infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.